Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 16/20 | 0.67 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043377 | 1.00 | ERBB2 (0.67) | ERBB2MINK1CYP19A1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL5049282 | 0.99 | ERBB2 (0.66) | ERBB2MINK1CYP19A1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL5049284 | 0.99 | ERBB2 (0.66) | ERBB2MINK1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL5042897 | 0.94 | ERBB2 (0.60) | ERBB2MINK1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL5042908 | 0.94 | ERBB2 (0.60) | ERBB2MINK1CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL5049440 | 0.92 | ERBB2 (0.79) | ERBB2MINK1 | |
| SCHEMBL5049442 | 0.92 | ERBB2 (0.79) | ERBB2MINK1 | |
| SCHEMBL5050366 | 0.90 | ERBB2 (0.64) | ERBB2MINK1NCF1 | |
| SCHEMBL5050360 | 0.90 | ERBB2 (0.64) | ERBB2MINK1NCF1 | |
| SCHEMBL5046860 | 0.89 | ERBB2 (0.55) | ERBB2MINK1CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432291-B2 | Ether derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | claimed |
| EP-1727815-B1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2007-06-27 | — | — | EP | claimed |
| EP-1727815-A1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-06 | — | — | EP | claimed |
| WO-2005090338-A1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | claimed |
| US-20050209290-A1 | Novel ether derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2005-09-22 | — | — | US | claimed |
| US-7432291-B2 | Ether derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1727815-B1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2007-06-27 | — | — | EP | disclosed |
| EP-1727815-A1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005090338-A1 | ETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| US-20050209290-A1 | Novel ether derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209290-A1 | Novel ether derivatives | CYP2E1, CYP11B1, CYP11B2 | ERBB2 823/4885MINK1 2620/4885CYP19A1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.